

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation		
Given Name (First Name) Steven	2. Surname (Last Name) Pearson		3. Date 13-April-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Auth Alexander Tarlocha	
5. Manuscript Title Cost-Effectiveness of Angiotensin?Nep	rilysin Inhibition in Heart F	ailure with Reduced I	Ejection Fraction
6. Manuscript Identifying Number (if you k	now it)		
		_	
Section 2. The Work Under C	ionsideration for Publi	cation	
Did you or your institution at any time receany aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, do		ent, commercial, private foundation, etc.) for cudy design, manuscript preparation,
If yes, please fill out the appropriate inf Excess rows can be removed by pressir		ve more than one ent	ity press the "ADD" button to add a row.
Name of Institution/Company	Grant'	n-Financial Other?	Comments
Blue Shield of California Foundation	✓		
California Health Care Foundation	✓		
aura and John Arnold Foundation	✓		
Section 3. Relevant financial	activities outside the	submitted work.	
of compensation) with entities as describing the "Add +" box. You should re	ribed in the instructions. U port relationships that we	se one line for each e	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.
Are there any relevant conflicts of inter If yes, please fill out the appropriate inf			
Name of Entity	Grant	n-Financial Other	Comments
Aetna			Dues for annual Policy Summitt



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
AHIP				✓	Dues for annual Policy Summitt meeting put on by my organization
Anthem				√	Dues for annual Policy Summitt meeting put on by my organization
Blue Shield of California				✓	Dues for annual Policy Summitt meeting put on by my organization
CVS Caremark				✓	Dues for annual Policy Summitt meeting put on by my organization
Express Scripts				✓	Dues for annual Policy Summitt meeting put on by my organization
Harvard Pilgrim Health Care				✓	Dues for annual Policy Summitt meeting put on by my organization
OmedaRx				✓	Dues for annual Policy Summitt meeting put on by my organization
Jnited Healthcare				✓	Dues for annual Policy Summitt meeting put on by my organization
Kaiser Permanente				✓	Dues for annual Policy Summitt meeting put on by my organization
Premera Blue Cross				✓	Dues for annual Policy Summitt meeting put on by my organization
Astra Zeneca				✓	Dues for annual Policy Summitt meeting put on by my organization
Genentech				✓	Dues for annual Policy Summitt meeting put on by my organization
GlaxoSmithKline				✓	Dues for annual Policy Summitt meeting put on by my organization
Johnson & Johnson				✓	Dues for annual Policy Summitt meeting put on by my organization
Merck				✓	Dues for annual Policy Summitt meeting put on by my organization
National Pharmaceutical Council	✓			✓	Grant for development of value assessment framework and dues for annual Policy Summitt meeting put on by my organization
Takeda				√	Dues for annual Policy Summitt meeting put on by my organization
Pfizer				✓	Dues for annual Policy Summitt meeting put on by my organization
Novartis				✓	Dues for annual Policy Summitt meeting put on by my organization
illy				✓	Dues for annual Policy Summitt meeting put on by my organization



Section 4.	Intellectual Property Patents & Copyrights
Do you have an	y patents, whether planned, pending or issued, broadly relevant to the work? Yes 🗸 No
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Heidenreich

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1

administrative support, etc.



Section 1. Identifying I	nformation		
1. Given Name (First Name) Paul	2. Surname (Last Name) Heidenreich	3. Date 16-April-2016	
4. Are you the corresponding autho	r?	Corresponding Author's Name Sandhu	
5. Manuscript Title "Cost-Effectiveness of Angiotens	in?Neprilysin Inhibition in Heart F	Failure with Reduced Ejection Fraction"	
6. Manuscript Identifying Number (i M16-0057	f you know it)		
Section 2. The Work Un	der Consideration for Public	ation	
	cluding but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,	
Section 3. Relevant fina	ancial activities outside the s	ubmitted work	
Place a check in the appropriate of compensation) with entities as	boxes in the table to indicate who described in the instructions. Us ould report relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.	
Section 4. Intellectual F			
Intellectual F	Property Patents & Copyrig	hts	
Do you have any patents, whether	er planned, pending or issued, bro	oadly relevant to the work? Yes 🗸 No	

Heidenreich 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Heidenreich has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Heidenreich 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Continue			
Section 1. Identifying Information	ation		
Given Name (First Name) Daniel	2. Surname (Last Name) Ollendorf		3. Date 15-April-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author	or's Name
5. Manuscript Title "Cost-Effectiveness of Angiotensin-Nepr	ilysin Inhibition in Heart F	ailure with Reduced	Ejection Fraction"
6. Manuscript Identifying Number (if you known M16-0057	ow it)	_	
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the	but not limited to grants, da		
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If you hav	e more than one ent	ity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial Other?	Comments
aura and John Arnold Foundation	✓		
Blue Shield of California Foundation	✓		
California HealthCare Foundation	✓		
Section 3. Relevant financial a	activities outside the s	submitted work.	
Place a check in the appropriate boxes ir of compensation) with entities as describ clicking the "Add +" box. You should rep Are there any relevant conflicts of interes If yes, please fill out the appropriate info	oed in the instructions. Us ort relationships that wer st?	se one line for each e	ntity; add as many lines as you need by
Name of Entity	Grant'	n-Financial Other?	Comments
Aetna			Dues for annual Policy Summit



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
AHIP				✓	Dues for annual Policy Summit meeting put on by my organization
Anthem				✓	Dues for annual Policy Summit meeting put on by my organization
Blue Shield of California				✓	Dues for annual Policy Summit meeting put on by my organization
CVS Caremark				✓	Dues for annual Policy Summit meeting put on by my organization
Express Scripts				✓	Dues for annual Policy Summit meeting put on by my organization
Harvard Pilgrim Health Care				✓	Dues for annual Policy Summit meeting put on by my organization
OmedaRx				✓	Dues for annual Policy Summit meeting put on by my organization
Jnited Healthcare				✓	Dues for annual Policy Summit meeting put on by my organization
Kaiser Permanente				✓	Dues for annual Policy Summit meeting put on by my organization
Premera Blue Cross				✓	Dues for annual Policy Summit meeting put on by my organization
AstraZeneca				✓	Dues for annual Policy Summit meeting put on by my organization
Genentech				✓	Dues for annual Policy Summit meeting put on by my organization
GlaxoSmithKline				✓	Dues for annual Policy Summit meeting put on by my organization
Johnson & Johnson				✓	Dues for annual Policy Summit meeting put on by my organization
Merck				✓	Dues for annual Policy Summit meeting put on by my organization
National Pharmaceutical Council	✓			✓	Grant for development of value assessment framework and dues for annual Policy Summit meeting put on by my organization
Takeda				√	Dues for annual Policy Summit meeting put on by my organization
Pfizer				√	Dues for annual Policy Summit meeting put on by my organization
Novartis				✓	Dues for annual Policy Summit meeting put on by my organization
Eli Lilly				✓	Dues for annual Policy Summit meeting put on by my organization



Section 4.	Intellectual Property Patents & Copyrights				
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No				
Section 5.	Relationships not covered above				
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?				
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):				
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				

Dr. Ollendorf reports grants from Laura and John Arnold Foundation, grants from Blue Shield of California Foundation, grants from California HealthCare Foundation, during the conduct of the study; other from Aetna, other from AHIP, other from Anthem, other from Blue Shield of California, other from CVS Caremark, other from Express Scripts, other from Harvard Pilgrim Health Care, other from OmedaRx, other from United Healthcare, other from Kaiser Permanente, other from Premera Blue Cross, other from AstraZeneca, other from Genentech, other from GlaxoSmithKline, other from Johnson & Johnson, other from Merck, grants and other from National Pharmaceutical Council, other from Takeda, other from Pfizer, other from Novartis, other from Eli Lilly, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Sandhu 1



Section 1. Identifying In	formation							
1. Given Name (First Name) Alexander	2. Surname (Last Name) Sandhu	3. Date 16-April-2016						
4. Are you the corresponding author?	the corresponding author? Yes No							
5. Manuscript Title Cost-Effectiveness of Angiotensin–Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction								
6. Manuscript Identifying Number (if Manuscript Revision Request M16								
Section 2. The Work Und	ler Consideration for Publication							
	luding but not limited to grants, data monitorin	y (government, commercial, private foundation, etc.) for ng board, study design, manuscript preparation,						
Section 3. Relevant final	ncial activities outside the submitted	l work.						
of compensation) with entities as	described in the instructions. Use one line in the lin	nave financial relationships (regardless of amount for each entity; add as many lines as you need by during the 36 months prior to publication.						
Section 4. Intellectual Pr	operty Patents & Copyrights							
Do you have any patents, whether	planned, pending or issued, broadly relev	ant to the work? Yes V No						

Sandhu 2



Section 5. Polationships not sovered above							
Relationships not covered above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Statement							
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
Dr. Sandhu has nothing to disclose.							

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Sandhu 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Chapman 1



Section 1. Identifying Inf	ormation						
1. Given Name (First Name) Richard	2. Surname (Last Name) Chapman	3. Date 11-May-2016					
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Alexander T. Sandhu					
5. Manuscript Title Cost-Effectiveness of Angiotensin–Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction							
6. Manuscript Identifying Number (if y	ou know it)						
Section 2. The Work Under Consideration for Publication							
	uding but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,					
Section 3. Relevant finan	cial activities outside the s	submitted work.					
Place a check in the appropriate bo of compensation) with entities as d	exes in the table to indicate wh escribed in the instructions. Used to report relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.					
Section 4. Intellectual Pro	operty Patents & Copyri	ghts					
Do you have any patents, whether							

Chapman 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Chapman has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Chapman 3